VERA News and Press, Vera Therapeutics Inc. From 06/12/23

2023-06-12 12:05:53 ET Shares of Vera Therapeutics (NASDAQ: VERA) were up more than 18.8% Monday morning, after climbing as high as 25% shortly after the market opened. The healthcare stock 's move was likely triggered after one competitor with a similar lead therapy saw positiv...

2023-06-12 10:43:42 ET Kidney disease drug developer Chinook Therapeutics ( KDNY ) added ~56% on Monday after announcing a $3.5B buyout deal with Novartis ( NVS ), sending the shares of its rival Vera Therapeutics ( NASDAQ: VERA ) sharply higher. Per the terms, the S...

BRISBANE, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s m...

2023-06-07 14:30:11 ET Vera Therapeutics ( NASDAQ: VERA ) has initiated a pivotal Phase 3 study of its drug candidate atacicept for the treatment of IgA nephropathy, an autoimmune kidney disorder also known as Berger's disease. The company will be testing the therapy on IgA neph...

Pivotal Phase 3 Trial for Atacicept in IgA Nephropathy Initiated Today Late-breaking results of ORIGIN Phase 2b trial supporting further evaluation of atacicept 150 mg as a potential disease-modifying treatment for IgAN will be presented at 60th European Renal Association (ERA) Congress...

2023-05-11 12:12:12 ET Vera Therapeutics press release ( NASDAQ: VERA ): Q1 GAAP EPS of -$0.80 misses by $0.20 . $197.2 million cash, cash equivalents, and marketable securities as of March 31, 2023 expected to fund operations to early 2026 For further details se...

36-week data from the Phase 2b ORIGIN clinical trial of atacicept in IgAN selected for presentation as a late breaking clinical trial at ERA Congress 2023 Plan to initiate a pivotal Phase 3 clinical trial of atacicept in IgAN during the second quarter of 2023 Strong balance sheet ...

BRISBANE, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological disease, today announced the appointment of Kerry Cooper, M.D.,...

2023-04-26 00:15:28 ET Summary After bringing you the first quarter installment covering large-cap and mid-cap insider activity, today's article will focus on the latest insider activity within the small-cap range. We believe that insiders supply the market with high-quality infor...

2023-04-18 00:41:35 ET Summary Shares of immunological disorder concern Vera Therapeutics, Inc. cratered 75% in early January despite its immunoglobulin A nephropathy candidate achieving its primary endpoint. The data were not overwhelming but certainly enough to advance atacicept...